Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Operating Leases (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Operating Leases for 4 consecutive years, with $1.1 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Leases fell 21.34% to $1.1 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.1 million, a 21.34% decrease, with the full-year FY2024 number at $1.7 million, up 62.52% from a year prior.
  • Operating Leases was $1.1 million for Q3 2025 at Orchestra BioMed Holdings, down from $1.3 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $1.7 million in Q4 2024 to a low of $1.0 million in Q4 2023.
  • A 4-year average of $1.3 million and a median of $1.3 million in 2023 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: crashed 38.32% in 2023, then surged 62.52% in 2024.
  • Orchestra BioMed Holdings' Operating Leases stood at $1.7 million in 2022, then tumbled by 38.32% to $1.0 million in 2023, then soared by 62.52% to $1.7 million in 2024, then plummeted by 32.72% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Operating Leases are $1.1 million (Q3 2025), $1.3 million (Q2 2025), and $1.5 million (Q1 2025).